CRO vs CDMO: What Each Does, How They Differ, and How to Choose

CRO vs CDMO: The Short Answer

A CRO (contract research organization) does research and development work for a drug sponsor: it runs preclinical studies and clinical trials, manages and analyzes the data, and prepares regulatory submissions. A CDMO (contract development and manufacturing organization) develops the process for making the drug and then manufactures it, from the first clinical batches to commercial supply.

Put simply, the CRO produces the evidence and the CDMO produces the product. Almost every drug program uses both, often at the same time: while a CRO runs a Phase 2 trial, a CDMO scales up the process that will supply Phase 3 and launch. Most biotechs outsource both functions entirely, because building clinical operations and GMP plants in-house costs far more than a young company can justify.

What Is a CRO?

US regulations give the cleanest definition. Under 21 CFR 312.3, a contract research organization is a person that assumes, as an independent contractor with the sponsor, one or more of the obligations of a sponsor, such as designing a protocol, selecting or monitoring investigations, evaluating reports and preparing materials for the FDA. A sponsor can transfer any or all of those obligations, but under 21 CFR 312.52 the transfer must be described in writing, and anything not written down stays with the sponsor. The CRO is then subject to the same regulatory action as a sponsor for the obligations it takes on.

International good clinical practice says the same thing in different words: a sponsor can delegate trial activities to service providers, but it keeps ultimate responsibility for the trial and the reliability of its results. That principle shapes every CRO relationship. The sponsor must oversee the CRO, not simply pay it.

CRO services usually fall into five groups:

• Discovery and preclinical: pharmacology, toxicology and safety studies needed before first-in-human dosing.
• Clinical operations: site selection, patient recruitment, monitoring and project management for Phase 1 to 4 trials.
• Data management and biostatistics: collecting, cleaning and analyzing trial data to regulatory standards.
• Regulatory affairs: preparing and submitting IND, NDA, BLA and international filings.
• Safety and pharmacovigilance: adverse-event reporting during trials and after approval.

Providers range from global full-service CROs that can run a multinational Phase 3 trial, to specialists in a phase, a therapeutic area or a region. Preclinical work is dominated by companies such as Charles River, while regional players such as Novotech in Asia-Pacific and Tigermed in China compete on speed and access to patients. Our China CRO landscape covers the Chinese providers in detail.

What Is a CDMO?

A CDMO develops and manufactures drugs for other companies. The “development” half covers process development (working out how to make the molecule reliably and at scale), analytical method development, formulation, scale-up and technology transfer. The “manufacturing” half covers GMP production of the active ingredient (drug substance) and the finished dose (drug product), including sterile fill-finish and packaging.

The term grew out of the older CMO (contract manufacturing organization) model, in which the client handed over a finished process and the contractor simply ran it. As more drugs came from small biotechs without process development teams, manufacturers added development services, and most now call themselves CDMOs.

Outsourcing manufacturing does not outsource responsibility. The FDA’s guidance on contract manufacturing arrangements makes the product owner responsible for the quality of drugs made under contract and expects both parties to set out their responsibilities in a written quality agreement: who approves batch release, who handles deviations, who manages changes, and how the owner audits the site.

The Key Differences

The comparison table above summarizes the practical differences. Three of them matter most when you plan a program.

1. Output. A CRO’s deliverable is data that must stand up to regulators. A CDMO’s deliverable is physical product that must meet specification, batch after batch.
2. Regulatory regime. CROs work under good clinical and laboratory practice and are inspected around clinical trials. CDMOs work under good manufacturing practice and face pre-approval and routine facility inspections. A failed manufacturing inspection can delay an approval even when the clinical data are excellent.
3. Time horizon. CRO contracts usually follow individual studies. CDMO relationships tend to run for years, from clinical supply through commercial production, because switching is slow and expensive.

When Each Partner Comes In

CRO and CDMO work runs in parallel from the first animal studies to launch. The table shows what each typically does at each stage of a drug program.

The point where the two meet is the IND. A first-in-human trial needs both a safety package from the CRO and clinical material made under GMP by the CDMO, so a delay on either side delays the trial. Planning the manufacturing timeline as carefully as the clinical one is one of the simplest ways a biotech can protect its schedule.

CRDMOs and Integrated Providers

Some providers now offer both sides. WuXi AppTec popularized the term CRDMO (contract research, development and manufacturing organization) for a model that takes a molecule from discovery through clinical supply and commercial production. Thermo Fisher, which owns the PPD clinical research business and the Patheon manufacturing network, offers a similar breadth from the US.

Integration has real advantages: fewer hand-offs, one contract, shared data and faster transitions between stages. The trade-off is concentration. If a single provider runs research, development and supply, a quality, capacity or geopolitical problem at that provider affects the whole program at once. Many sponsors therefore integrate early, when speed matters most, and add a second manufacturing source before pivotal trials.

The Largest CROs and CDMOs

Both markets are large and led by a handful of global companies. MarketsandMarkets puts the CRO services market at about $84.6 billion in 2025, rising to about $126 billion by 2030 (8.3% a year). Pharmaceutical CDMO estimates vary more with definitions: Precedence Research puts the market at about $197 billion in 2025, while BCC Research sized it at $136.6 billion in 2024. The table shows 2025 revenue from the largest providers that report comparable figures.

Other major providers include Thermo Fisher (PPD and Patheon), Catalent (owned by Novo Holdings since December 2024), FUJIFILM Biotechnologies, Boehringer Ingelheim and AGC Biologics on the manufacturing side, and Fortrea, Parexel and Syneos Health among CROs. Our CDMO market analysis goes deeper on manufacturing capacity, segments and pricing trends.

How Contracts and Pricing Work

CROs mostly work on study budgets. A full-service contract prices each task (start-up, monitoring visits, data management, statistics) and adds pass-through costs such as investigator grants and travel. Budgets grow through change orders when a protocol is amended or enrollment runs slow, which is why experienced sponsors negotiate change-order rules as carefully as the headline price. In the alternative functional service provider (FSP) model, the sponsor rents dedicated CRO staff for a function such as monitoring or biostatistics and manages the work itself.

CDMOs price development work as fee-based projects, then charge per batch for manufacturing. For commercial supply and scarce capacity, contracts often include capacity reservations or minimum-volume commitments. Those terms can outlive the program they were signed for, so they matter in any later licensing or sale of the asset.

How to Choose a CRO

• Relevant experience: trials in your indication and phase, with enrollment results you can verify.
• Patient access: sites and regions where your patients actually are, including whether data from those regions will be accepted by the FDA and EMA.
• The real team: meet the project manager and clinical leads who will run your study, not only the bid team.
• Data systems and quality: audit history, inspection outcomes and data-integrity controls.
• Contract terms: change-order rules, pass-through handling, performance incentives and data ownership.

How to Choose a CDMO

• Modality fit: real experience with your molecule type, whether small molecule, antibody, ADC, peptide or cell and gene therapy.
• Inspection record: FDA and EMA inspection history for the specific site that will make your product.
• Capacity through launch: whether the site can supply Phase 3 and commercial volumes, not only early batches.
• Technology transfer terms: who owns the process knowledge, and how easily it can move to a second source.
• Geography and policy risk: where the product is made and whether that location could restrict future buyers.

BIOSECURE, China and Supply Risk

Provider choice has become a policy question. The BIOSECURE Act, signed on December 18, 2025 as part of the FY2026 National Defense Authorization Act, bars US federal agencies from procuring biotechnology equipment or services from designated “biotechnology companies of concern” and from contracting with companies that use them. The law names no companies; designation runs through the Pentagon’s 1260H list and an Office of Management and Budget list due by December 2026, and the prohibitions are not expected to apply until around 2028, with a transition period for existing contracts.

The exposure is wide. In a 2024 BIO survey of 124 biopharma companies, 79% had at least one contract or product with a China-based or China-owned CDMO. Most sponsors are not ripping out Chinese providers, which remain fast and cost-effective, especially for discovery and early development. Instead they map which parts of a program rely on which provider, and plan a second source for anything that a future US buyer or federal customer would need moved.

Why It Matters in a Licensing Deal

When a pharma company licenses or acquires an asset, it inherits the CRO data and the CDMO supply chain behind it. Diligence teams therefore look closely at both. On the clinical side they audit data quality, CRO oversight and whether trial sites will satisfy the FDA. On the manufacturing side they review the quality agreement, inspection history, process ownership, how easily the process can be transferred, and supply terms that will bind the buyer.

Weak answers cost money. Unclear process ownership, a single-source supplier with policy exposure, or minimum-volume commitments that do not fit the buyer’s plans are all used to push down upfront payments or to add supply conditions to the term sheet. Our pharma due diligence checklist lists what buyers check, and our term sheet guide covers how supply and technology-transfer terms are written into cross-border deals.

Glossary of Outsourcing Terms

CRO

Contract research organization: runs research, clinical trials, data management and regulatory work for a sponsor.

CDMO

Contract development and manufacturing organization: develops the manufacturing process and makes the drug under GMP.

CMO

Contract manufacturing organization: manufactures using a process the client provides, without development work.

CRDMO

A provider that combines contract research with development and manufacturing.

FSP

Functional service provider: a CRO model in which the sponsor hires dedicated staff for a function and manages the work.

Drug substance and drug product

The active ingredient (drug substance) and the finished dosage form a patient receives (drug product).

Technology transfer

Moving a manufacturing process and its know-how from one site to another, with the testing needed to show the product is the same.

Quality agreement

The written agreement that sets out the quality responsibilities of a drug’s owner and its contract manufacturer.

Master services agreement

The framework contract with a CRO or CDMO; individual projects then run under work orders or statements of work.

The Bottom Line

A CRO generates the evidence; a CDMO makes the product. Both are outsourced by most biotechs, both leave final responsibility with the sponsor, and both are now scrutinized by buyers and regulators as part of the asset itself. The right choice balances experience, quality and cost with a clear view of supply risk, including where the work is done.

If you are preparing an asset for partnering and want its CRO and CDMO arrangements to support, rather than weaken, its value, talk to our team.